The efficacy of clindamycin in the treatment of experimental endocarditis in rabbits was compared with that of nafcillin. Both drugs were administered intramuscularly three times daily for 5 days, clindamycin at doses of 6.25, 12.5, 25, or 50 mg/kg and nafcillin at a dose of 200 mg/kg. The minimum inhibitory and bactericidal concentrations (0.125 Fg/ml) of clindamycin for the test strain of Staphylococcus aureus were very similar to the corresponding concentrations (0.25 ,ug/ml) of nafcillin. The effectiveness of clindamycin against the experimental endocarditis was dose dependent. The therapeutic accomplishments of the two highest clindamycin doses were equivalent to those attained with 200 mg of nafcillin per kg. The rates of sterilization of vegetations were equal when the serum bactericidal titers of these drugs were .1:8. In special situations the administration of clindamycin in high doses could prove useful in the treatment of S. aureus endocarditis.
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Staphylococcus aureus is a major cause of bacterial endocarditis. Despite the introduction of new semisynthetic antibiotics and surgical techniques, significant morbidity and mortality (5, 13, 15) still occur as a result of this disease, especially in the nonaddicted population (1) . The overall mortality rate of patients with staphylococcal endocarditis treated with nafcillin, or its equivalent, is approximately 40%o (13) .
Approximately 80%o of patients with S. aureus endocarditis are cured with clindamycin therapy (2); however, clinical experience is limited and confined almost exclusively to heroin addicts with tricuspid valve disease, for which there is a low mortality rate irrespective of the drug regimen (1, 2). Although clindamycin is active against S. aureus in vitro, its usefulness in treating endocarditis may be limited for several reasons: (i) it may be less bactericidal than the penicillins; (ii) resistant strains are encountered occasionally (10) ; (iii) resistance may develop during therapy in experimental animals (8) and in humans (12) ; and (iv) pseudomembranous colitis may develop. The latter reaction does not appear to be dose related and is less prominent when clindamycin is administered parenterally. The other obstacles listed might be eliminated with higher doses of clindamycin. Finally, the suitability of this agent for intramuscular administration gives it an important advantage over the semisynthetic penicillins or vancomycin in the therapy of heroin addicts, in whom superficial veins are often absent. These considerations led us to an evaluation of the therapeutic effectiveness of clindamycin and nafcillin against experimentally induced staphylococcal endocarditis in rabbits.
MATERIALS AND METHODS Test orgnism. The S. aureus strain used in the in vivo studies was isolated from a patient with endocarditis. Its characteristics were described in an earlier study (7) . The minimum inhibitory and bactericidal concentrations of clindamycin for this strain were identical (0.125 ,ug/ml); the corresponding concentrations of nafcillin were also identical (0.25 ,ug/ml).
Production of endocarditis. Experimental endocarditis was induced in New Zealand white rabbits (2 to 3 kg) by modifications of techniques described previously (7). The animals were anesthetized with pentobarbital sodium administered intravenously. A polyethylene catheter (PE-90; Clay Adams) was then inserted through the right carotid artery into the left ventricle, the aortic valve was traumatized for 15 Endocarditis, which developed in 95% of the rabbits, was verified 24 h after inoculation by the pres- Experimental design. Only those animals with positive blood cultures 24 h after inoculation were retained in the study because positive blood cultures correlate directly with the presence of endocarditis (7). Treatment with cindamycin or nafcillin was initiated at that time. Both drugs were administered intramuscularly every 8 h for 5 days, clindamycin at doses of 6.25, 12.5, 25.0, or 50.0 mg/kg and nafcillin at a dose of 200 mg/kg. On day 2 of therapy, serum was obtained and stored at -70°C for measurement of serum antibiotic levels and inhibitory and bactericidal titers. This period of storage (c2 weeks) did not influence the assay results. Sixteen untreated animals served as controls.
All of the animals were killed 8 h after the last doses of antibiotic were given. The hearts were removed aseptically, and the aortic vegetations were excised and weighed (range, 0.05 to .0.4 g). After homogenization in the Teflon tissue grinder, the vegetations were diluted serially on Trypticase soy agar pour plates and incubated at 37°C for 24 h. Sterile vegetations were expressed as loglo 2.0 CFU/g, as the largest weight plated was 0.1 g, and the lower limit of sensitivity was approximately 100 CFU/g. 60 min after administration and closely approximated those found in humans (Fig. 1) . The serum concentration of nafcillin at 30 min was 49.5 ,ug/ ml; this declined to 6.6 ag/ml by 8 h, with a serum beta half-life of 2.4 h. The peak concentrations of clindamycin were obtained at either 30 or 60 min and were 3.3, 4.3, 6.2, and 11.9 ,ug/ml for the 6.25-, 12.5-, 25-, and 50-mg/kg doses, respectively. Trough levels were between 0.3 and 2.8 xg/ml, depending on the dose used. The serum beta halflife for clindamycin was 3.7 h. Serum bactericidal activity. Although there was some interanimal variation, the serum bactericidal titers closely correlated with the mean serum levels of the drug ( Table 2 ). The serum bactericidal titers in rabbits treated with nafcillin were highest at 30 min (1:128 to 1:256) and were 1:16 in all animals just before administration of the next dose. The serum bactericidal titers observed with clindamycin were dose dependent and ranged from peak titers of 1:32 to 1:256 in the two high-dose groups to 1:16 to 1:32 in the low-dose groups (Table 2) . Trough serum bactericidal titers were .1:8 only for the two highdose groups.
DISCUSSION
This study showed that clindamycin at doses of 25 and 50 mg/kg is as elffective as nafcillin at a dose of 200 mg/kg in the treatment of experimental staphylococcal endocarditis in rabbits. Optimal results were obtained when peak serum concentrations of clindamycin exceeded 6.2 ,ug/ ml, levels achievable with standard parenteral doses in humans; resistance to clindamycin was not observed. It should be recognized that all experiments were done to assess the results of therapy for 5 days, an arbitrary endpoint. More prolonged therapy might well be more effective.
These studies clearly showed the dose dependence of clindamycin in the treatment of experimental staphylococcal endocarditis. Results equivalent to those attained with nafcillin were achieved with clindamycin only when peak serum concentrations of clindamycin exceeded 6.2
,ug/ml. These levels are slightly higher than those obtained after intramuscular administration of 300 to 600 mg in normal volunteers (3).
The best results were attained in our study when serum levels of cindamycin reached approximately 11 ,ug/ml; concentrations in this range require intravenous infusion of 600 to 900 mg in normal persons, but serum levels may need to be higher in infected patients (4) . The doses usually used in treating endocarditis in humans (450 to 600 mg administered intramuscularly or intravenously every 6 h [2, 12] ) may be suboptimal.
The relationship between the therapeutic results obtained with clindamycin and the serum bactericidal titers is interesting. For instance, 14 of 22 valves from rabbits receiving the two higher doses of clindamycin were culture negative (-loglo 2.0 CFU/g) postmortem. In contrast, only three valves from the 25 rabbits receiving the two lower doses of clindamycin were similarly negative (Table 1) . Favorable results were obtained with those clindamycin regimens that produced trough serum bactericidal titers of .1:8 (Table 2) . Because the dosage interval (8 h) was held constant for all the clindamycin regimens, it was not possible to discern the relative contribution to the therapeutic outcome of achieving a certain peak or trough serum bactericidal titer. However, the data do suggest that maintenance of an adequate serum bactericidal titer during most of the dosage interval may be more important than the actual serum bactericidal titer achieved. This concept has been emphasized recently (9) . Comparable data on serum bactericidal titers during clindamycin therapy of endocarditis in humans are not available.
Clinical experience with clindamycin therapy of staphylococcal endocarditis is limited essentially to tricuspid valve disease in intravenous drug abusers (2, 12) , in whom mortality is characteristically low (1). Our study examined aortic vlve disease, which generally produces significant morbidity and mortality. The overall success rate of clindamycin therapy of staphylococcal endocarditis in humans is approximately 80%; in our experimental model, favorable results were obtained in 64% of the animals receiving the two highest clindamycin doses. No differences were seen between the effects of semisynthetic penicillin therapy and clindamycin therapy in staphylococcal endocarditis in a recent study (6) ; in several patients, clindamycin was substituted for cephalothin or vancomycin because of intolerance to either of the latter agents (6). Intravenous clindamycin followed by oral clindamycin was curative in several patients (6) . It is possible that therapeutic success could be improved by clindamycin-aminoglycoside combinations because these agents are often synergistic in vitro (14) . In addition, other actions of clindamycin may be important in treating endocarditis. These may include an alteration in bacterial virulence factors at subinhibitory concentrations (G. (11) .
Our experiments showed that clindamycin (at appropriate serum concentrations and serum bactericidal titers) is as effective as nafcillin in the treatment of experimental staphylococcal endocarditis. Clindamycin should not be considered the drug of choice for this disease, primarily because it has a slow bactericidal activity as compared with penicillins or cephalosporins (8, 14) . Although clindamycin may be effective at full parenteral doses in the treatment of S. aureus endocarditis, it should be reserved for situations in which antistaphylococcal penicillins, cephalothin, cefazolin, or vancomycin have either failed or are poorly tolerated.
